Suppliers / Takeda Pharmaceuticals (formerly Nycomed)
Takeda Pharmaceuticals (formerly Nycomed)
Germany 825 employees Updated 9 July 2026
Takeda Pharmaceuticals (formerly Nycomed) is a finished-dose manufacturer based in Germany. It appears in 1 regulatory filing across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by ANVISA (Brazil) and US FDA. Its most recent recorded inspection, by US FDA, closed on 12 April 2024 as NAI.
3
registered plants
2 with an FDA FEI number
1
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 12 April 2024 NAI US FDA
- 6 November 2023 VAI US FDA
- 19 July 2021 VAI US FDA
- 26 November 2019 OAI US FDA
- 9 August 2019 VAI US FDA
- 7 November 2017 NAI US FDA
- 29 August 2017 NAI US FDA
- 30 October 2015 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| OSAKA, Japan | Not on file |
| Japan, Japan | 3004664162 |
| Japan, Japan | 3002808311 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| EDA (EG) | 1 | None |
| ANVISA (Brazil) | None | 3 |
| US FDA | None | 2 |
Comparing suppliers?
Choose your molecules and target markets. Takeda Pharmaceuticals (formerly Nycomed) comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was NAI, on 12 April 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates